TITLE

Erythropoietin and cancer death rates

PUB. DATE
May 2008
SOURCE
Hospice Management Advisor;May2008, Vol. 13 Issue 5, p59
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article focuses on the meta-analysis which suggests that erythropoiesis-stimulating agents (ESAs) may increase the risk of death in cancer patients. It reveals that the ESAs are associated with the risk of venous thromboembolism (VTE). Researchers compared ESAs and a placebo in the treatment of cancer patients with anemia. They found that patients who received ESAs have a higher risk of VTE, which raised concerns regarding the safety of ESA administration to cancer patients.
ACCESSION #
31872282

 

Related Articles

  • Anaemia drug raises clot risk.  // GP: General Practitioner;2/29/2008, p14 

    The article reports that treating anemia in cancer patients with erythropoiesis-stimulating agents (ESAs) can increase blood clot risk as stated in the U.S. research findings. According to the author, anemia in cancer is often treated with erythropoeitin and darbepoetin but there have been...

  • 2008 - Review: Erythropoiesis-stimulating agents increase mortality and venous thromboembolism in cancer-associated anemia. Thomé, Stephan // ACP Journal Club;8/19/2008, Vol. 149 Issue 2, p6 

    The article focuses on a study regarding the role of erythropoiesis-stimulating agents (ESAs) in increasing mortality and venous thromboembolism in cancer patients with anemia and presents the author's views on it. It describes the procedure of the study, which showed that ESAs increased...

  • Erythropoietin and Cancer Death Rates.  // OB/GYN Clinical Alert;Apr2008, Vol. 24 Issue 12, Special section p1 

    The article focuses on a new meta-analysis which reflects that erythropoiesis-stimulating agents (ESAs) may increase the risk of death in cancer patients. The meta-analysis also suggests that the drugs are associated with a significant risk of venous thromboembolism (VTE). The authors of the...

  • Erythropoietin and Cancer Death Rates. Elliott, William T. // Clinical Oncology Alert;Apr2008, Vol. 24 Issue 4, p1 

    The article focuses on the results of a meta-analysis which found that erythropoiesis-stimulating agents (ESA) may increase the risk of death in patients with cancer. It also suggests that the drugs are related with a higher risk of venous thromboembolism (VTE). It concludes that the ESA...

  • Erythropoietin and Cancer Death Rates.  // Infectious Disease Alert;Apr2008, Vol. 27 Issue 7, p1 

    The article focuses on the results of a meta-analysis which found that erythropoiesis-stimulating agents (ESA) may increase the risk of death in patients with cancer. It also suggests that the drugs are related with a higher risk of venous thromboembolism (VTE). It concludes that the ESA...

  • Erythropoietin and Cancer Death Rates.  // Clinical Cardiology Alert;Apr2008, Vol. 27 Issue 4, p1 

    The article focuses on the results of a meta-analysis which found that erythropoiesis-stimulating agents (ESAs) may increase the risk of death in patients with cancer. It also suggests that the drugs are related with a higher risk of venous thromboembolism (VTE). It concludes that the ESA...

  • Read? Olsson, Carl A. // AUANews;May2008, Vol. 13 Issue 5, p21 

    The article discusses research being done on cancer linked anemia and calcium oxalate kidney stones. It references studies by D. W. Kaufman et al, published in the 2008 issue of "Journal of the American Society of Nephrology," and by S. M. Silver et al, published in the 2008 issue of "Journal of...

  • Effects of erythropoiesis-stimulating agents on fatigue- and anaemia-related symptoms in cancer patients: systematic review and meta-analyses of published and unpublished data. Bohlius, J; Tonia, T; Nüesch, E; Jüni, P; Fey, M F; Egger, M; Bernhard, J // British Journal of Cancer;7/8/2014, Vol. 111 Issue 1, p33 

    Background:Erythropoiesis-stimulating agents (ESAs) reduce the need for red blood cell transfusions; however, they increase the risk of thromboembolic events and mortality. The impact of ESAs on quality of life (QoL) is controversial and led to different recommendations of medical societies and...

  • Erythropoiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes. Glaspy, J.; Crawford, J.; Vansteenkiste, J.; Henry, D.; Rao, S.; Bowers, P.; Berlin, J. A.; Tomita, D.; Bridges, K.; Ludwig, H. // British Journal of Cancer;1/19/2010, Vol. 102 Issue 2, p301 

    BACKGROUND: Cancer patients often develop the potentially debilitating condition of anaemia. Numerous controlled studies indicate that erythropoiesis-stimulating agents (ESAs) can raise haemoglobin levels and reduce transfusion requirements in anaemic cancer patients receiving chemotherapy. To...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics